Previous 10 | Next 10 |
WESTMINSTER, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that it has submitted a Patent Cooperat...
ARCA biopharma (NASDAQ:ABIO): Q2 GAAP EPS of -$0.34. Cash and cash equivalents of $63.2M Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 expanded to South America Topline data anticipated in the fourth quarter of 2021 Shares +3.06% AH. Press Release For ...
Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 expanded to South America Topline data anticipated in the fourth quarter of 2021 WESTMINSTER, Colo., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a bioph...
Analysis in full patient cohort shows Gencaro effect compared to standard of care In the GENETIC-AF entire cohort of heart failure patients treated with Gencaro, compared to patients treated with metoprolol succinate (TOPROL-XL), experienced: a 36% reduction in cumulative atrial...
Shares of ARCA biopharma Inc. (NASDAQ:ABIO) traded today at $2.75, breaking its 52-week low. So far today approximately 102,000 shares have been exchanged, as compared to an average 30-day volume of 237,000 shares. In the past 52 weeks, ARCA biopharma Inc. share prices are bracketed by a...
Gilnature/iStock via Getty Images ARCA biopharma ([[ABIO]] -9.2%) provides an update on ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19. ARCA has received approval from regulatory authorities in Argentina and Brazi...
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients Trial expanded to South America, with regulatory approvals for Argentina and Brazil Target trial enrollment increased to 160 patients Topline trial data antici...
WESTMINSTER, Colo., July 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Thomas Keuer , Chief Operating...
7 Top Reddit Penny Stocks to Watch in July 2021 Finding penny stocks on Reddit is a favorite choice among all types of investors. While there are plenty of Reddit penny stocks to choose from, only a handful are showing value right now. It’s difficult to say for certain which ...
ARCA biopharma (ABIO) has entered into a patent assignment agreement with the University Medical Center of Johannes Gutenberg University Mainz, Germany.Under the agreement, ARCA receives exclusive world-wide patent rights to the use of rNAPc2 as a potential treatment for COVID-19, and other i...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / May 22, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sale...
ARCA biopharma and Oruka Therapeutics announce Merger Agreement ARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company app...